Delcath Q3 2025 revenue $20.6M (+84% YoY); net income $0.8M; FY revenue guidance $83-85M

DELCATH SYSTEMS, INC.

2025-Q3 EPS reported $0.12 vs consensus $0.02 ▲ beat (+488.2%)

Q3 total revenue $20.6M (+84% YoY); HEPZATO revenue $19.3M, CHEMOSAT $1.3M.
Net income $0.8M (down from $1.9M YoY) due to higher R&D ($8M vs $3.9M) and SG&A ($10.3M vs $7M).
Non-GAAP adjusted EBITDA $5.3M (vs $1M YoY); cash & investments $88.9M, no debt.
FY 2025 guidance: revenue $83-85M (150% volume growth), gross margins 85-87%, positive EBITDA & cash flow each quarter.
Clinical progress: Phase 2 CRC trial dosed first patient; CHOPIN trial showed improved survival; 25 active U.S. centers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.